Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18689403 | 0.96 | MAPT (0.51) | MAPTTP53POLBTDP1KMT2A | |
| SCHEMBL18688805 | 0.95 | MAPT (0.54) | MAPTTP53POLBKMT2AMEN1 | |
| SCHEMBL18688795 | 0.92 | LMNA (0.45) | MAPTTDP1KMT2AMEN1HTT | |
| SCHEMBL18689423 | 0.89 | KMT2A (0.49) | MAPTPOLBKMT2AMEN1LMNA | |
| SCHEMBL18688798 | 0.89 | KMT2A (0.51) | MAPTTP53KMT2AMEN1LMNA | |
| SCHEMBL18688794 | 0.88 | MAPT (0.50) | MAPTTP53POLBTDP1KMT2A | |
| SCHEMBL18689406 | 0.87 | SLC1A3 (0.54) | MAPTTP53POLBTDP1KMT2A | |
| SCHEMBL18688797 | 0.86 | MEN1 (0.46) | KMT2AMEN1HTTSMN1; SMN2LMNA | |
| SCHEMBL18688791 | 0.86 | KMT2A (0.50) | MAPTPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL18688793 | 0.84 | RXFP1 (0.48) | MAPTTDP1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353156-B1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10696642-B2 | TEAD transcription factor autopalmitoylation inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180215721-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2018-08-02 | — | — | US | disclosed |
| WO-2017053706-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696642-B2 | TEAD transcription factor autopalmitoylation inhibitors | TEAD1, TEAD2, TEAD3 | MAPT 1926/4885TP53 536/4885POLB 1930/4885 |
| US-20180215721-A1 | TEAD TRANSCRIPTION FACTOR AUTOPALMITOYLATION INHIBITORS | TEAD1, TEAD2, TEAD3 | MAPT 1926/4885TP53 536/4885POLB 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.